Senseonics Holdings

SENS · NYSE American

$8.21+$0.195 (+2.43%)TodayMarket closed · Oct 20, 7:54 PM ET

Prev close $8.02

SENS analyst rating

BuyConsensus of 6 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy4
Hold2
Underperform0
Sell0

12-month price target · 7 analysts

Average $14.48 (+76.4% upside)

Low: $8.08
Now: $8.21
High: $18.90

Upgrades and downgrades

The latest rating actions, newest first

SENS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Oct 7, 2026	Initiates	Equal-Weight	$10.00	68%
Mizuho	Jul 15, 2026	Maintains	Outperform	$20.00 → $18.00	56%
HC Wainwright & Co.	May 12, 2026	Maintains	Buy	$18.50 → $14.00	42%
Stifel	May 11, 2026	Maintains	Hold	$9.00 → $8.00	55%
HC Wainwright & Co.	Nov 6, 2025	Maintains	Buy	$1.40 → $18.50	42%
TD Cowen	Nov 5, 2025	Maintains	Buy	$25.00 → $15.00	48%
Barclays	Nov 5, 2025	Maintains	Overweight	$1.50 → $31.00	57%
Stifel	Oct 21, 2025	Initiates	Hold	$9.00	55%

The case for and against

Updated Dec 29, 2025

Bull case

Senseonics Holdings Inc. is projected to achieve total revenues of $75.6 million in 2026 and $118.4 million in 2027, demonstrating significant growth from prior financial forecasts. The company's gross margins are anticipated to surpass 50% by the end of next year, reflecting an upward trend from 43% in Q3, which is an improvement from 36% in the first half of 2025. Additionally, the company has experienced a remarkable 90% year-over-year increase in topline revenue, driven by a substantial influx of new patients transitioning to the Eversense 365 glucose monitoring system.

Bear case

Senseonics Holdings Inc. has projected that its revenues for the first half of 2025 will remain relatively flat, largely due to the conversion of previous U.S. operations, which raises concerns about its growth prospects in a competitive market. Despite reporting quarterly revenues of $8.1 million, slightly exceeding consensus estimates, the company also posted a net loss of $0.43 per share, which was greater than the expected net loss of $0.40 per share. This combination of stagnant revenue expectations and increasing losses highlights the financial challenges the company faces, contributing to a negative outlook on its stock performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.